This article is a correction to a systematic review and meta-analysis on vimentin expression as a prognostic marker in pancreatic cancer.[5][1] The study precisely quantified the association between vimentin expression in tumor cells and clinicopathological features, including overall survival (OS), tumor stage, lymph node status, and distant metastases.[1][3] Vimentin expression is significantly associated with shortened OS (pooled logHR = 1.39, 95% CI: 0.11–2.68, p = 0.034), although with high heterogeneity (I² = 93.64%, p < 0.001).[1][3] It is also significantly associated with a higher lymph node stage (N-stage; pooled logOR = 0.58, 95% CI: 0.08–1.08, p = 0.022), with minimal heterogeneity (I² = 0%, p = 0.418).[3] No significant association was found with primary T-stage (pooled logOR = -0.10, 95% CI: -0.87–0.66, p = 0.791) or M-stage (pooled OR = 0.08, 95% CI: -0.95–1.10, p = 0.882).[1] Publication bias was minimal for N- and T-stages, but significant for OS analysis.[1][3]